BPC-157 Side Effects (What the Limited Human Data Show)

By DoseGauge Editorial · Updated 2026-06-12 · 5 min read

BPC-157 has no FDA-established human safety profile. It is not approved by the FDA for any indication, no agency has reviewed a human adverse-effect profile for it, and the published human data are very limited. Most of what is written about its tolerability comes from animal studies, which do not transfer cleanly to people. The honest summary is that the absence of robust human safety data is the central fact here, not a list of side effects that anyone can call complete. This page reports what the cited reviews say. It is information, not a claim that BPC-157 is safe.

What the human evidence shows

The published human evidence on BPC-157 is thin. The 2025 narrative review by McGuire and colleagues identified only three published studies examining BPC-157 in humans, each with a small sample size (on the order of 2 to 16 participants) and without the rigorous design features, such as control groups, that would let anyone draw firm safety conclusions. The 2025 review by Józwiak and colleagues reaches a similar position: human studies are scarce, and there are no completed clinical studies establishing efficacy in people.

There is also a Phase I trial that was initiated in 2015 and never published. Because its results were never reported in peer-reviewed literature, it cannot be used to characterize a human safety profile. The McGuire review's own conclusion is that until well-designed human trials are conducted, BPC-157 should be considered investigational and approached with caution.

What follows from this is narrow but important. With so few human participants studied and no completed safety review, there is no reliable human adverse-effect rate to report. Saying BPC-157 has "few side effects" would overstate what the data can support. The accurate statement is that the human safety picture is largely unknown.

What animal studies report

Most of the BPC-157 literature is preclinical, meaning cell-culture and animal work. In those models, researchers have described the peptide as well tolerated at the doses studied, with the reviews noting tissue-repair and protective effects in rodents. These are animal findings.

Animal tolerability does not establish human safety. Species differ in metabolism, dosing scale, and exposure, and a compound that looks benign in a short rodent study can behave differently in people over longer periods. The animal elimination half-life reported in the literature is under 30 minutes, but that is a rodent and canine value that has not been validated in humans and cannot be assumed to apply to them. Treat the preclinical safety signals as background context about what has been studied, not as evidence that BPC-157 is safe for human use.

Regulatory status

BPC-157 is not FDA-approved for any indication, and its compounding status has moved more than once. The FDA placed it on the Category 2 bulk drug list in September 2023, a designation that flagged it as not appropriate for compounding pending more data on safety, impurities, and the limited human evidence. In April 2026 the FDA removed it from Category 2 after the original nominations were withdrawn. That removal did not approve the peptide or add it to the 503A bulk drug substances list; it returned BPC-157 to an unresolved status. As of June 2026 it is not on the approved 503A compounding list, and a Pharmacy Compounding Advisory Committee (PCAC) review is scheduled for July 2026.

The reason this belongs in a discussion of side effects is that the regulatory record reflects the same gap as the scientific record: there is not enough human safety evidence to support approval, and the agency's actions have turned on that uncertainty rather than on a finished safety determination.

Why "is it safe" has no clean answer

People searching for BPC-157 side effects usually want a yes or no on safety. The data do not support either. There is no FDA-established human safety profile, the published human studies are too few and too small to define an adverse-effect rate, and the favorable tolerability reports come from animals. That combination means the honest answer is that the risks are not well characterized in humans, which is different from saying the risks are low.

DoseGauge does not assess safety, and the calculator on this site does not either. It performs reconstitution and unit math on the values you enter and makes no judgment about whether a dose, or the compound itself, is safe for you. A safety question about a specific person is a clinical question for a licensed clinician.

Frequently asked questions

Is BPC-157 safe?

There is no FDA-established human safety profile for BPC-157, and the published human data are too limited to define one. Most tolerability information comes from animal studies, which do not transfer to humans. This page cannot tell you BPC-157 is safe, because the evidence to support that statement does not exist. A licensed clinician is the right person to discuss risk for an individual.

What are the known side effects of BPC-157 in humans?

No reliable human adverse-effect profile has been established, because only a few small human studies exist and no FDA safety review has been completed. Animal studies describe the peptide as well tolerated at the doses tested, but those are animal findings that do not establish what happens in people.

Has the FDA reviewed BPC-157 for safety?

The FDA has not approved BPC-157 or completed a safety determination that establishes a human adverse-effect profile. It placed the peptide on the Category 2 bulk drug list in September 2023, removed it from that list in April 2026 after the nominations were withdrawn, and has a Pharmacy Compounding Advisory Committee review scheduled for July 2026. As of June 2026 it is not on the approved 503A compounding list.

Informational and educational only. Not medical advice. DoseGauge computes from the values you enter and does not recommend a dose. Talk to a licensed clinician before using any peptide or GLP-1 medication.